• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Unmasking survival biases in observational treatment studies of influenza patients

tetano

Editor, Senior Moderator
J Clin Epidemiol. 2017 Feb 7. pii: S0895-4356(16)30266-9. doi: 10.1016/j.jclinepi.2017.01.008. [Epub ahead of print]
[h=1]Unmasking survival biases in observational treatment studies of influenza patients.[/h] Wolkewitz M[SUP]1[/SUP], Schumacher M[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Several observational studies reported that Oseltamivir (Tamiflu) reduced mortality in infected and hospitalized patients. Due to the restriction of observation to hospital stay and time-dependent treatment assignment, such findings were prone to common types of survival bias (length, time-dependent and competing risk bias).
[h=4]METHODS:[/h] British hospital data from the FLU-CIN study group were used which included 1391 patients with confirmed pandemic influenza A/H1N1 2009 infection. We used a multi- state model approach with following states: hospital admission, Oseltamivir treatment, discharge and death. Time origin is influenza onset. We displayed individual data, risk sets, hazards and probabilities from multi-state models to study the impact of these three common survival biases.
[h=4]RESULTS:[/h] The correct hazard ratio of Oseltamivir for death was 1.03 (95%-CI: 0.64-1.66) and for discharge 1.89 (95%-CI: 1.65-2.16). Length bias increased both hazard ratios: HR(death)= 1.82 (95%-CI:1.12-2.98) and HR(discharge)= 4.44 (95%-CI: 3.90-5.05) whereas the time-dependent bias reduced them: HR(death)= 0.62 (95%-CI:0.39-1.00) and HR(discharge)= 0.85 (95%-CI:0.75-0.97). Length and time-dependent bias were less pronounced in terms of probabilities. Ignoring discharge as a competing event for hospital death led to a remarkable overestimation of hospital mortality and failed to detect the reducing effect of Oseltamivir on hospital stay.
[h=4]CONCLUSIONS:[/h] The impact of each of the three survival biases was remarkable and it can make NI ap- pear more effective or even harmful. Incorrect and misclassified risk sets were primary the source of biased hazard rates.
Copyright ? 2017. Published by Elsevier Inc.


[h=4]KEYWORDS:[/h] Tamiflu; competing risk bias; length bias; neuraminidase inhibitors; time-dependent bias

PMID: 28188897 DOI: 10.1016/j.jclinepi.2017.01.008
[PubMed - as supplied by publisher]
 
Back
Top Bottom